Progesterone attenuation of alpha 1-adrenergic receptor stimulation of phosphoinositol hydrolysis in hypothalamus of estrogen-primed female rats.
These experiments examined whether the previously observed abolition by progesterone (P) of alpha 1-adrenergic potentiation of adenylyl cyclase activity in brain slices of estrogen-primed female rats is attributable to a reduced capacity of alpha 1-adrenoceptors to stimulate phosphoinositol hydrolysis. In preoptic area and hypothalamic slices from ovariectomized (OVX) female rats, both norepinephrine (NE) and the alpha 1-adrenergic agonist phenylephrine (PHE) were robust stimulators of inositol phosphate (IP) formation. The NE response was completely blocked by the alpha 1-adrenergic antagonist prazosin. PHE-induced IP formation in tissue from OVX females exposed for 48 h to estrogen alone was comparable to that in OVX controls. In hypothalamic tissue from OVX rats given estrogen plus P, NE and PHE activation of phosphoinositol hydrolysis was attenuated. Both chlorethylclonidine, an irreversible antagonist of alpha 1b-adrenoceptors, and 5-methylurapidil, an alpha 1a-selective antagonist, reduced NE-induced IP formation regardless of the hormonal condition of the animals. Analysis of PHE competition for [3H]prazosin binding indicated that agonist binding was of high affinity (Ki, 16-30 microM) and was unaffected by hormonal status. Therefore, P abolition of alpha 1-adrenergic augmentation of adenylyl cyclase is correlated with reduced phosphoinositol hydrolysis, but not with changes in alpha 1-adrenoceptor agonist binding affinity. Moreover, both alpha 1a- and alpha 1b-adrenoceptors appear to work together to stimulate this second messenger system in the female rat hypothalamus.
Karkanias
G B
GB
Departments of Neuroscience and Psychiatry, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Petitti
N
N
Etgen
A M
AM
D000262:Adenylyl Cyclases / Q000378:metabolism; D058646:Adrenergic alpha-1 Receptor Agonists; D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D006160:Guanosine Triphosphate / Q000494:pharmacology; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D066298:In Vitro Techniques; D007295:Inositol Phosphates / Q000378:metabolism*; D010052:Ovariectomy; D010656:Phenylephrine / Q000494:pharmacology*; D011301:Preoptic Area / Q000187:drug effects / Q000378:metabolism*; D011374:Progesterone / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*
D058646:Adrenergic alpha-1 Receptor Agonists; D007295:Inositol Phosphates; D018340:Receptors, Adrenergic, alpha-1; D010656:Phenylephrine; D006165:Guanylyl Imidodiphosphate; D011374:Progesterone; D004958:Estradiol; D006160:Guanosine Triphosphate; D000262:Adenylyl Cyclases